I-MASS: Prevention & At Home Treatment Mass Distribution Protocol for COVID-19
The FLCCC I-MASS Protocol was created for generalized distribution during mass outbreaks and in low-resource countries. To achieve maximal impact as well as ease of deployment with the lowest burden of required elements, the I-MASS treatment approach is centered on the fewest, core, high impact elements such as the drug Ivermectin, an anti-parasitic medicine that is on the WHO’s list of essential medicines, has been given 3.7 billion times around the globe, and has won the Nobel prize in 2015 for its global and historic impacts in eradicating endemic parasitic infections in many parts of the world.Ivermectin has proven to be highly potent against COVID-19. It has shown antiviral and anti-inflammatory properties in observational and randomized controlled studies conducted throughout the world. Practitioners and Health Ministries who have adopted Ivermectin in treatment protocols report significant reductions in time to recovery, hospitalizations, and death. The use of Ivermectin as prophylaxis and prevention has also been proven in studies to reduce the spread of infection and offer protection to high-risk individuals.
Also included in the protocol are Vitamin D3, Melatonin, Aspirin, a multivitamin, a thermometer, and an antiseptic mouthwash.
Prevention ProtocolFor adults > 18 years and >40 kg/90 lbs
- Ivermectin 18 mg – start treatment with one dose on day 1, and then repeat weekly (every 7 days)
- Vitamin D3 2000 IU (50 mcg) daily
- Multivitamin 1 tablet daily
- Digital thermometer optional (to watch the body temperature)
- Ivermectin 24 mg – daily for 5 days In the setting of poor clinical response, advanced disease, or obesity, higher doses should be used (target 0.4–0.6 mg/kg)
- Melatonin 6 mg at night for 5 days
- Aspirin (ASA) 80 mg/day (unless contraindicated)
- Anti-septic mouth wash Three times daily (gargle do not swallow); if available
- Ivermectin 18 mg – repeat dose in 48 hours
The evidence for supporting the other vitamins and medicine can be found here: https://covid19criticalcare.com/covid-19-protocols/medical-evidence-and-optional-medicines/.
The FLCCC peer-reviewed paper summarizing this data has been published in the American Journal of Therapeutics: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088823/.
Further supportive information can also be found here: https://covid19criticalcare.com/ivermectin-in-covid-19/.
Additional treatment protocols for COVID-19, including for hospitalized patients, can be found at https://covid19criticalcare.com/covid-19-protocols/.
Support for Ivermectin in the use of prophylaxis can be found here: https://scivisionpub.com/pdfs/ivermectin-as-prophylaxis-against-covid19-retrospective-cases-evaluati…
Disclaimer: The safety of Ivermectin in pregnancy has not been established. Particularly the use in the 1st trimester should be discussed with your doctor beforehand.